Search clinical trials for: Losmapimod

Total 15 results

Fulcrum Therapeutics

Terminated

Losmapimod Safety and Efficacy in COVID-19 (LOSVID)

COVID-19

United States, Mexico, Brazil, Peru
Fulcrum Therapeutics

Active, not recruiting

Efficacy and Safety of Losmapimod in Treating Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) (REACH)

Facioscapulohumeral Muscular Dystrophy (FSHD)

United States, Spain, Italy, Denmark, Canada, Germany, France, Netherlands, United Kingdom
Fulcrum Therapeutics

Active, not recruiting

Evaluation of Safety, Tolerability, and Changes in Biomarker and Clinical Outcome Assessments of Losmapimod for FSHD1 With Extension (FSHD)

Facioscapulohumeral Muscular Dystrophy 1

Netherlands
Fulcrum Therapeutics

Active, not recruiting

Efficacy and Safety of Losmapimod in Treating Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD) With Open-Label Extension (OLE)

Facioscapulohumeral Muscular Dystrophy (FSHD)

United States, Canada, France, Spain
Fulcrum Therapeutics

Completed

Efficacy and Safety of Losmapimod in Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD) (FSHD)

Facioscapulohumeral Muscular Dystrophy (FSHD)

United States, Canada, France, Spain
Fulcrum Therapeutics

Completed

Relative Bioavailability and Food Effect Study of Losmapimod 15 mg Tablets

Healthy Adult Subjects

United States
GlaxoSmithKline

Completed

A Study to Evaluate the Effects of 3 Months Dosing With GW856553, as Assessed FDG-PET/CT Imaging

Atherosclerosis

United Kingdom
GlaxoSmithKline

Completed

Safety and Efficacy Study of Losmapimod (GW856553) in Frequently Exacerbating Participants With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Argentina, Spain, Chile, Germany, Korea, Republic of, Bulgaria, Brazil, Slovakia
GlaxoSmithKline

Completed

Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-centre, Dose Ranging Study to Evaluate the Efficacy and Safety of Losmapimod Tablets Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease (COPD).

Pulmonary Disease, Chronic Obstructive

United States, Argentina, Germany, Estonia, Ukraine, Korea, Republic of, Norway, Czechia
GlaxoSmithKline

Completed

Phase I Study of GW856553 (Losmapimod)

Acute Coronary Syndrome

Australia
GlaxoSmithKline

Completed

PK Study of IV Formulation of GW856553

Cardiovascular Disease

United Kingdom
GlaxoSmithKline

Completed

A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS)

Glomerulosclerosis, Focal Segmental

United States, Canada
GlaxoSmithKline

Completed

A Study to Evaluate the Effect of Losmapimod on Cardiac Conduction as Compared to Placebo and Moxifloxacin

Acute Coronary Syndrome

United States
GlaxoSmithKline
The TIMI Study Group

Completed

A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60) (LATITUDE)

Acute Coronary Syndrome

United States, Australia, France, Spain, Taiwan, Estonia, Poland, Russian Federation, Belgium, Philippines, Sweden, Thailand, Germany, Israel, Bulgaria, Hong Kong, Netherlands, Norway, Slovakia, South Africa, Korea, Republic of, R... and more
Cambridge University Hospitals NHS Foundation Trust
GlaxoSmithKline; University of Cambridge; Royal Brompton & Harefield NHS Foundation... and other collaborators

Completed

Losmapimod in Chronic Obstructive Pulmonary Disease Patients Stratified by Fibrinogen. (EVOLUTION)

Chronic Obstructive Pulmonary Disease

United Kingdom

Search clinical trials for: Losmapimod

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bangladesh

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations